also labeled PNB-0408) is a synthetic oligopeptide derived from angiotensin IV, developed in the Harding and Wright labs at Washington State University and later commercialized through M3 Biotechnology and Athira Pharma
Researchers should follow their institutions storage protocols and consult the product storage guidance where applicable
Peptides are chains of amino acids, and in solution they are chemically fragile
If youre currently taking medication, we would recommend checking with a doctor or medical professional before taking this supplement
a figure that many patients on GLP-1 therapy fall short of, partly because the appetite suppression the medications produce makes hitting protein targets without conscious effort difficult. Clinical note Patients on GLP-1 therapy frequently report that protein-rich foods (particularly meat and eggs) become less palatable during treatment
Third-Party Testing Because the FDA does not regulate supplements, third-party testing provides independent verification of a NMN supplements safety, purity, and label accuracy
